176 related articles for article (PubMed ID: 38352574)
1. The spatial structure of the tumor immune microenvironment can explain and predict patient response in high-grade serous carcinoma.
Van Kleunen L; Ahmadian M; Post MD; Wolsky RJ; Rickert C; Jordan K; Hu J; Richer JK; Marjon NA; Behbakht K; Sikora MJ; Bitler BG; Clauset A
bioRxiv; 2024 Jan; ():. PubMed ID: 38352574
[TBL] [Abstract][Full Text] [Related]
2. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.
Jäntti T; Luhtala S; Mäenpää J; Staff S
Tumour Biol; 2020 Nov; 42(11):1010428320971404. PubMed ID: 33169632
[TBL] [Abstract][Full Text] [Related]
3. Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment across tumor types.
Ptacek J; Locke D; Finck R; Cvijic ME; Li Z; Tarolli JG; Aksoy M; Sigal Y; Zhang Y; Newgren M; Finn J
Lab Invest; 2020 Aug; 100(8):1111-1123. PubMed ID: 32203152
[TBL] [Abstract][Full Text] [Related]
4. Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages.
Nersesian S; Arseneau RJ; Mejia JP; Lee SN; Westhaver LP; Griffiths NW; Grantham SR; Meunier L; Communal L; Mukherjee A; Mes-Masson AM; Arnason T; Nelson BH; Boudreau JE
Front Immunol; 2023; 14():1307873. PubMed ID: 38318505
[TBL] [Abstract][Full Text] [Related]
5. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
[TBL] [Abstract][Full Text] [Related]
6. Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
Taube ET; Denkert C; Sehouli J; Kunze CA; Dietel M; Braicu I; Letsch A; Darb-Esfahani S
Gynecol Oncol; 2016 Mar; 140(3):494-502. PubMed ID: 26721227
[TBL] [Abstract][Full Text] [Related]
7. The Spatial Context of Tumor-Infiltrating Immune Cells Associates with Improved Ovarian Cancer Survival.
Steinhart B; Jordan KR; Bapat J; Post MD; Brubaker LW; Bitler BG; Wrobel J
Mol Cancer Res; 2021 Dec; 19(12):1973-1979. PubMed ID: 34615692
[TBL] [Abstract][Full Text] [Related]
8. Spatially resolved transcriptomics of high-grade serous ovarian carcinoma.
Stur E; Corvigno S; Xu M; Chen K; Tan Y; Lee S; Liu J; Ricco E; Kraushaar D; Castro P; Zhang J; Sood AK
iScience; 2022 Mar; 25(3):103923. PubMed ID: 35252817
[TBL] [Abstract][Full Text] [Related]
9. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
[TBL] [Abstract][Full Text] [Related]
10. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response.
Yang H; Gu X; Fan R; Zhu Q; Zhong S; Wan X; Chen Q; Zhu L; Feng F
J Ovarian Res; 2023 Nov; 16(1):223. PubMed ID: 37993916
[TBL] [Abstract][Full Text] [Related]
11. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
Front Immunol; 2022; 13():923194. PubMed ID: 35935940
[TBL] [Abstract][Full Text] [Related]
12. Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer.
Rączkowska A; Paśnik I; Kukiełka M; Nicoś M; Budzinska MA; Kucharczyk T; Szumiło J; Krawczyk P; Crosetto N; Szczurek E
BMC Cancer; 2022 Sep; 22(1):1001. PubMed ID: 36131239
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
15. The Role of the Extracellular Matrix and Tumor-Infiltrating Immune Cells in the Prognostication of High-Grade Serous Ovarian Cancer.
Belotti Y; Lim EH; Lim CT
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053566
[TBL] [Abstract][Full Text] [Related]
16. ALOX5AP Predicts Poor Prognosis by Enhancing M2 Macrophages Polarization and Immunosuppression in Serous Ovarian Cancer Microenvironment.
Ye X; An L; Wang X; Zhang C; Huang W; Sun C; Li R; Ma H; Wang H; Gao M
Front Oncol; 2021; 11():675104. PubMed ID: 34094977
[TBL] [Abstract][Full Text] [Related]
17. Assessment and statistical modeling of the relationship between remotely sensed aerosol optical depth and PM2.5 in the eastern United States.
Paciorek CJ; Liu Y;
Res Rep Health Eff Inst; 2012 May; (167):5-83; discussion 85-91. PubMed ID: 22838153
[TBL] [Abstract][Full Text] [Related]
18. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
[TBL] [Abstract][Full Text] [Related]
19. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
20. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
